

## **OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership**

**NANTES, France, April 5, 2018, 07:30 a.m. CET – OSE Immunotherapeutics** (ISIN: FR0012127173; Mnémo: OSE), today announced that it will host an audio/web conference to discuss its global immuno-oncology partnership agreement with Boehringer Ingelheim on **Thursday, April 5, 2018 at 6:00 p.m. CET (12:00 p.m. EDT).**

***Conference audio/web details:***

**Thursday, April 5th @ 6:00 PM CET**

**Audio connection numbers:**

France Toll: +33170710159 PIN: 40510188#

United Kingdom Toll: +442071943759 PIN: 40510188#

United States Toll-Free: +18442860643 PIN: 40510188#

**Webconference:**

**<https://www.anywhereconference.com?Conference=418751388&PIN=40510188&UserAudioMode=DATA>**

**Audio playback numbers and reference (available during 90 days from the conference call):**

France +33 (0)1 72 72 74 02

UK +44 20 3364 5147

US +1 (646) 722-4969

Access code: 418751388#

### **ABOUT OSE Immunotherapeutics**

OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Neoepitopes innovation (Tedopi®) is today in Phase 3 in advanced lung cancers (NSCLC) after Checkpoint Inhibitors failure (anti PD-1 and anti PD-L1). A global license and collaboration agreement was signed in April 2018 with Boehringer Ingelheim to develop checkpoint inhibitor OSE-172 (anti-SIRPa monoclonal antibody), for the treatment of advanced solid tumors.

An option to license was exercised in July 2016 by Janssen Biotech to continue clinical development of FR104 (an anti CD28 mAb) in auto-immune diseases after positive phase 1 results. A 2-step license option was signed in 2017 with Servier Laboratories to develop OSE-127 to develop the product up to the completion of a phase 2 clinical trial planned in autoimmune bowel disease and Sjogren disease.



The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases. Its first-in-class clinical portfolio offers a diversified risk profile.

For more information, please visit: <http://ose-immuno.com/en/>.

Click and follow us on Twitter and LinkedIn



#### Contacts

##### **OSE Immunotherapeutics**

Sylvie Détry

[Sylvie.detry@ose-immuno.com](mailto:Sylvie.detry@ose-immuno.com)

+33 143 297 857

##### **French Media: FP2COM**

Florence Portejoie

[fportejoie@fp2com.fr](mailto:fportejoie@fp2com.fr)

+33 607 768 283

##### **U.S. Media: LifeSci Public Relations**

Matt Middleman, M.D.

[matt@lifescipublicrelations.com](mailto:matt@lifescipublicrelations.com)

+1 646 627 8384

##### **U.S. and European Investors**

Chris Maggos

[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

+41 79 367 6254

#### ***Forward-looking statements***

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import.

Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 28 April 2017 under the number R.17-038, including the annual financial report for the fiscal year 2016, available on the OSE Immunotherapeutics' website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.